Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial
暂无分享,去创建一个
M. Ychou | M. Stern | F. Bidard | J. Pierga | R. Guimbaud | O. Bouché | T. Mazard | F. Ghiringhelli | P. Mariani | L. Mineur | C. Proudhon | M. Rivoire | D. Moussata | C. Decraene | S. Thézénas | L. Cabel | J. Madic | A. Rampanou | E. François | A. Saliou | F. Khemissa-Akouz | Nicolas Kiavue | T. Stanbury | N. Kiavue | Adrien Saliou | M. Stern
[1] M. Masařík,et al. Prognostic Significance of Serum Free Amino Acids in Head and Neck Cancers , 2019, Cells.
[2] Raja R. Narayan,et al. Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer , 2019, Annals of Surgical Oncology.
[3] Gabriella Sozzi,et al. Tumor Extracellular Matrix Remodeling: New Perspectives as a Circulating Tool in the Diagnosis and Prognosis of Solid Tumors , 2019, Cells.
[4] G. Giannini,et al. Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer , 2019, Cancers.
[5] Leonie L. Zeune,et al. Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap) , 2018, International journal of cancer.
[6] K. Kinzler,et al. Serial circulating tumor DNA (ctDNA) analysis as a prognostic marker and a real-time indicator of adjuvant chemotherapy (CT) efficacy in stage III colon cancer (CC). , 2018 .
[7] P. Laurent-Puig,et al. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] A. Vincent-Salomon,et al. Multiple Hotspot Mutations Scanning by Single Droplet Digital PCR. , 2018, Clinical chemistry.
[9] S M Keating,et al. Lessons Learned: Transfer of the High‐Definition Circulating Tumor Cell Assay Platform to Development as a Commercialized Clinical Assay Platform , 2017, Clinical pharmacology and therapeutics.
[10] P. Laurent-Puig,et al. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study) , 2017, Clinical Cancer Research.
[11] Y. Rozenholc,et al. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study , 2016, PLoS medicine.
[12] R. Strausberg,et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer , 2016, Science Translational Medicine.
[13] I. Sobhani,et al. A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker. , 2016, Clinical chemistry.
[14] M. Ychou,et al. FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study—Prodige 14 – ACCORD 21 (METHEP-2), a unicancer GI trial. , 2016 .
[15] Stefanie S Jeffrey,et al. Circulating tumor cell technologies , 2016, Molecular oncology.
[16] R. Strausberg,et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] D. Sargent,et al. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. , 2015, The Lancet. Oncology.
[18] Beatriz Bellosillo,et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients , 2015, Nature Medicine.
[19] Olivier Lantz,et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients , 2015, International journal of cancer.
[20] I. Bièche,et al. Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types , 2015, Molecular oncology.
[21] P. Gao,et al. Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer , 2015, BMC Cancer.
[22] R. McCormack,et al. Gefitinib Treatment in EGFR Mutated Caucasian NSCLC , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[23] Franck Molina,et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA , 2014, Nature Medicine.
[24] V. Servois,et al. Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma , 2014, International journal of cancer.
[25] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[26] A. Abad,et al. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab. , 2013, Clinical colorectal cancer.
[27] P. Laurent-Puig,et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. , 2013, Clinical chemistry.
[28] Jorge S. Reis-Filho,et al. Going with the Flow: From Circulating Tumor Cells to DNA , 2013, Science Translational Medicine.
[29] M. Ychou,et al. A Randomized Phase II Trial of Three Intensified Chemotherapy Regimens in First-Line Treatment of Colorectal Cancer Patients with Initially Unresectable or Not Optimally Resectable Liver Metastases. The METHEP Trial , 2013, Annals of Surgical Oncology.
[30] F. Bidard,et al. Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] M. Ducreux,et al. Disseminated and circulating tumor cells in gastrointestinal oncology. , 2012, Critical reviews in oncology/hematology.
[32] Jean Salamero,et al. Microfluidic sorting and multimodal typing of cancer cells in self-assembled magnetic arrays , 2010, Proceedings of the National Academy of Sciences.
[33] I. Nagtegaal,et al. Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] Michael Morse,et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] L. Crinò,et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] D. Sargent,et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[37] Jonathan W. Uhr,et al. Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.
[38] Bernard Paule,et al. Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival , 2004, Annals of surgery.
[39] S. Goodman,et al. Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.